Next Generation DNA Sequencing in Probing Tumour Origins and Behaviour in Haematological Malignancy
Surinder Sahota, Associate Professor/Reader, University of Southampton
Next generation sequencing (NGS) is providing an unparalleled
insight into the mutated tumour genome that is heritable by malignant progeny,
and which propagates disease. At the whole exome sequencing (WES) level, NGS
provides specific insights into how genes are dysregulated that allow both
functional studies and predictions, as well as identifying cellular and
molecular pathways for new therapeutics. These data are also pivotal to
understanding tumour origins and progression. My presentation will focus on
haematological malignancy, and in particular on mature B-lymphoid neoplasms,
and will describe NGS approaches that have allowed unique insights into origins
of human multiple myeloma (MM), a disease of malignant plasma cells that
accumulate in the bone marrow, and remains essentially incurable. It will
review key elements of the MM genome as have emerged from NGS studies, and our
work where we have profiled the tumour clone in response to therapy. These
findings have profiled tumour cells at the whole population level, but it is
abundantly clear that NGS of the tumour genome will now need to increasingly
focus on the single cell level, to fully delineate mechanisms of tumour
evolution and response to therapy. This approach which will be essential to
provide individualised therapy in cancer patients.
|
|